Literature DB >> 30242992

Detection of Flares by Decrease in Physical Activity, Collected Using Wearable Activity Trackers in Rheumatoid Arthritis or Axial Spondyloarthritis: An Application of Machine Learning Analyses in Rheumatology.

Laure Gossec1, Frédéric Guyard2, Didier Leroy2, Thomas Lafargue2, Michel Seiler3, Charlotte Jacquemin1, Anna Molto4, Jérémie Sellam5, Violaine Foltz1, Frédérique Gandjbakhch1, Christophe Hudry6, Stéphane Mitrovic1, Bruno Fautrel1, Hervé Servy7.   

Abstract

OBJECTIVE: Flares in rheumatoid arthritis (RA) and axial spondyloarthritis (SpA) may influence physical activity. The aim of this study was to assess longitudinally the association between patient-reported flares and activity-tracker-provided steps per minute, using machine learning.
METHODS: This prospective observational study (ActConnect) included patients with definite RA or axial SpA. For a 3-month time period, physical activity was assessed continuously by number of steps/minute, using a consumer grade activity tracker, and flares were self-assessed weekly. Machine-learning techniques were applied to the data set. After intrapatient normalization of the physical activity data, multiclass Bayesian methods were used to calculate sensitivities, specificities, and predictive values of the machine-generated models of physical activity in order to predict patient-reported flares.
RESULTS: Overall, 155 patients (1,339 weekly flare assessments and 224,952 hours of physical activity assessments) were analyzed. The mean ± SD age for patients with RA (n = 82) was 48.9 ± 12.6 years and was 41.2 ± 10.3 years for those with axial SpA (n = 73). The mean ± SD disease duration was 10.5 ± 8.8 years for patients with RA and 10.8 ± 9.1 years for those with axial SpA. Fourteen patients with RA (17.1%) and 41 patients with axial SpA (56.2%) were male. Disease was well-controlled (Disease Activity Score in 28 joints mean ± SD 2.2 ± 1.2; Bath Ankylosing Spondylitis Disease Activity Index score mean ± SD 3.1 ± 2.0), but flares were frequent (22.7% of all weekly assessments). The model generated by machine learning performed well against patient-reported flares (mean sensitivity 96% [95% confidence interval (95% CI) 94-97%], mean specificity 97% [95% CI 96-97%], mean positive predictive value 91% [95% CI 88-96%], and negative predictive value 99% [95% CI 98-100%]). Sensitivity analyses were confirmatory.
CONCLUSION: Although these pilot findings will have to be confirmed, the correct detection of flares by machine-learning processing of activity tracker data provides a framework for future studies of remote-control monitoring of disease activity, with great precision and minimal patient burden.
© 2018, American College of Rheumatology.

Entities:  

Year:  2019        PMID: 30242992     DOI: 10.1002/acr.23768

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  24 in total

1.  Detection of Familial Mediterranean Fever attacks by using a connected activity tracker and assessment of impact of attacks to daily physical activities: a pilot study.

Authors:  Hakan Babaoglu; Ozkan Varan; Nuh Atas; Hasan Satis; Reyhan Salman; Mehmet Akif Ozturk; Berna Goker; Seminur Haznedaroglu; Abdurrahman Tufan
Journal:  Clin Rheumatol       Date:  2019-03-02       Impact factor: 2.980

2.  Digital crowdsourcing: unleashing its power in rheumatology.

Authors:  Martin Krusche; Gerd R Burmester; Johannes Knitza
Journal:  Ann Rheum Dis       Date:  2020-06-11       Impact factor: 19.103

3.  Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendations.

Authors:  Joanna Kedra; Timothy Radstake; Aridaman Pandit; Xenofon Baraliakos; Francis Berenbaum; Axel Finckh; Bruno Fautrel; Tanja A Stamm; David Gomez-Cabrero; Christian Pristipino; Remy Choquet; Hervé Servy; Simon Stones; Gerd Burmester; Laure Gossec
Journal:  RMD Open       Date:  2019-07-18

4.  German Mobile Apps in Rheumatology: Review and Analysis Using the Mobile Application Rating Scale (MARS).

Authors:  Johannes Knitza; Koray Tascilar; Eva-Maria Messner; Marco Meyer; Diana Vossen; Almut Pulla; Philipp Bosch; Julia Kittler; Arnd Kleyer; Philipp Sewerin; Johanna Mucke; Isabell Haase; David Simon; Martin Krusche
Journal:  JMIR Mhealth Uhealth       Date:  2019-08-05       Impact factor: 4.773

Review 5.  Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap.

Authors:  Atul Deodhar; Lianne S Gensler; Marina Magrey; Jessica A Walsh; Adam Winseck; Daniel Grant; Philip J Mease
Journal:  Rheumatol Ther       Date:  2019-10-31

Review 6.  [Perspectives for rheumatological health services research at the German Rheumatism Research Center].

Authors:  K Albrecht; F Milatz; J Callhoff; I Redeker; K Minden; A Strangfeld; A Regierer
Journal:  Z Rheumatol       Date:  2020-12-01       Impact factor: 1.372

7.  A Thorough Examination of Morning Activity Patterns in Adults with Arthritis and Healthy Controls Using Actigraphy Data.

Authors:  Alison Keogh; Niladri Sett; Seamas Donnelly; Ronan Mullan; Diana Gheta; Martina Maher-Donnelly; Vittorio Illiano; Francesc Calvo; Jonas F Dorn; Brian Mac Namee; Brian Caulfield
Journal:  Digit Biomark       Date:  2020-09-23

8.  Physical activity measured using wearable activity tracking devices associated with gout flares.

Authors:  Nada Elmagboul; Brian W Coburn; Jeffrey Foster; Amy Mudano; Joshua Melnick; Debra Bergman; Shuo Yang; Lang Chen; Cooper Filby; Ted R Mikuls; Jeffrey R Curtis; Kenneth Saag
Journal:  Arthritis Res Ther       Date:  2020-08-03       Impact factor: 5.156

Review 9.  A systematic review of the applications of artificial intelligence and machine learning in autoimmune diseases.

Authors:  I S Stafford; M Kellermann; E Mossotto; R M Beattie; B D MacArthur; S Ennis
Journal:  NPJ Digit Med       Date:  2020-03-09

10.  Assessment of the many faces of PsA: single and composite measures in PsA clinical trials.

Authors:  Dylan McGagh; Laura C Coates
Journal:  Rheumatology (Oxford)       Date:  2020-03-01       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.